A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported
outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with
pembrolizumab alone in patients with previously untreated advanced melanoma.

Inclusion Criteria:

- Histologically confirmed metastatic (recurrent or de novo Stage IV) or unresectable
locally advanced (Stage IIIC or IIID) cutaneous, acral, or mucosal melanoma;

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;

- Life expectancy >/= 12 weeks;

- Adequate hematologic and end-organ function;

- Naive to prior systemic anti-cancer therapy for advanced melanoma with some
exceptions;

- Tumor specimen availability;

- Measurable disease per RECIST v1.1.

Exclusion criteria:

- Ocular/uveal melanoma;

- Any anti-cancer therapy with the exceptions as specified in the protocol;

- Symptomatic, untreated, or actively progressing central nervous system (CNS)
metastases;

- Previous splenectomy;

- History of autoimmune disease;

- Prior allogeneic bone marrow transplantation or prior solid organ transplantation;

- Positive test for Human Immunodeficiency Virus (HIV) infection;

- Active hepatitis B or C or tuberculosis;

- Significant cardiovascular disease;

- Known clinically significant liver disease.